risdiplam sold brand name evrysdi medication used treat spinal muscular atrophy first oral medication approved treat risdiplam survival motor neuron rna splicing clinical trials common adverse events included fever diarrhea rash ulcers mouth area joint pain arthralgia urinary tract additional adverse events observed infantileonset population included upper respiratory tract infection pneumonia constipation risdiplam approved us food drug administration fda august treatment adults children two months age developed association ptc therapeutics sma marketed us subsidiary united states risdiplam indicated treat people two months age older spinal muscular two clinical trials following adverse events occurred least frequently patients treated risdiplam placebo group fever diarrhoea rash ulcers mouth area joint pain arthralgia urinary tract additional adverse events infantileonset population included upper respiratory tract infection pneumonia constipation risdiplam taken together medications multidrug toxin extrusion mate substrates risdiplam may increase plasma concentrations risdiplam addresses underlying cause sma reduced amount survival motor neuron smn protein protein encoded genes sma caused mutations code inactive forms protein activity gene produces much smaller quantities smn tends determine severity compound pyridazine derivative modifies splicing messenger rna include exon resulting increase concentration functional smn protein nusinersen first drug approved treat sma antisense oligonucleotide targeting intronic splicing silencer also alters mrna splicing safety efficacy risdiplam infantileonset lateronset sma evaluated ongoing clinical infantileonset sma study openlabel trial participants efficacy established based ability sit without support least five seconds months treatment participants able sit independently five seconds months treatment participants alive without permanent ventilation although study perform direct comparisons children receiving placebo inactive treatment results compare favourably typical course untreated study lateronset sma randomised controlled trial enrolled participants aged years less severe forms disease participants treated risdiplam months showed improvements motor function compared participants given us food drug administration fda awarded marketing approval genentech august fda earlier granted application risdiplam fast track priority review orphan drug genentech also awarded rare pediatric disease priority review european medicines agency ema awarded risdiplam priority medicine designation orphan drug designation august roche applied marketing authorisation brazil chile china european union indonesia russia south korea risdiplam international nonproprietary name since late roche offering drug globally free eligible people expanded access httpsenwikipediaorgwikirisdiplam